ClinicalTrials.gg
CompletedNCT02106390Updated Aug 22, 2018Results posted

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

A Phase 3 interventional study of Meningococcal group B Vaccine, rMenB+OMV NZ and Meningococcal ACWY Conjugate Vaccine, MenACWY in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 7 sites in 2 countries. Open to participants aged 85 Days to 119 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-22.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
85 Days to 119 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
10th of 21
750 · median 508
Started
2014
with 2 others
Phase 3
7 of 21
none open now
Registered
12th of 21
by date
Lead sponsor
6 of 21
GlaxoSmithKline

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 10th largest by enrollment, is one of 3 that started in 2014, is one of 7 in phase 3, and was the 12th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 85 Days to 119 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the immunogenicity, the safety and the tolerability of rMenB+OMV NZ and MenACWY vaccines in healthy infants, when concomitantly administered at 3, 5, 7 and 13 months of age, compared to either alone.

03

Conditions studied

  • Infections, Meningococcal

Keywords

  • Central Nervous System Diseases
  • Nervous System Diseases
  • Meningitis
04

Who can participate

Ages eligible
85 Days to 119 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy 3-month old infants (85-119 days, inclusive) at time of Visit 1 whose parents/legal guardians have given written after the nature of the study has been explained.
  2. Available for all the visits scheduled in the study.
  3. In good health as determined by medical history, physical examination and clinical judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  1. History of any previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s) at the time of enrollment.
  2. Previous known or suspected disease caused by N. meningitidis.
  3. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization.
  4. History of severe allergic reaction after previous vaccinations, or to any component of the vaccine.
  5. Known or suspected disease or impairment/alteration of the immune system resulting from, for ex-ample:

    • Chronic administration of or other immune-modifying drugs since birth (3 months prior). (For , this means prednisone, or equivalent, ≥ 0.5 mg/kg/day or ≥ 10 mcg/day for children below 2 years. Inhaled and topical steroids are allowed),
    • Immune deficiency disorder, or known infection.
  6. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation since birth.
  7. History of any progressive or severe neurologic disorder, or seizure disorder or Guillan Barré syndrome (exception: one self-limited febrile seizure is acceptable).
  8. History of any bleeding disorder considered as a to intramuscular injection or blood draw.
  9. Child's parent(s) or legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.
  10. Receipt of any or non-registered product since birth (3 month prior) or are expected to receive during the study period.
  11. Family members or household members of site research staff.
  12. Any clinically-significant chronic or progressive disease according to judgment of the investigator (pulmonary, cardiovascular, renal, hepatic or endocrine functional abnormality) or a congenital anomaly/known cytogenic disorder (e.g., Down's syndrome).
  13. History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
750 participants (actual)

Study arms

  • Experimental
    rMenB+ACWY

    Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.

    Biological: Meningococcal group B Vaccine, rMenB+OMV NZ · Biological: Meningococcal ACWY Conjugate Vaccine, MenACWY

  • Active comparator
    rMENB

    Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.

    Biological: Meningococcal group B Vaccine, rMenB+OMV NZ

  • Active comparator
    MenACWY

    Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.

    Biological: Meningococcal ACWY Conjugate Vaccine, MenACWY

Interventions

  • BiologicalMeningococcal group B Vaccine, rMenB+OMV NZ

    Drug page: 4CMenB vaccine

    4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.

    Also known as: Bexsero®

  • BiologicalMeningococcal ACWY Conjugate Vaccine, MenACWY

    4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.

    Also known as: Menveo®

06

What researchers measure

Primary outcomes

  1. Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against Each of the Serogroup B Indicator Strains

    Human serum bactericidal activity (hSBA) titers against each of the serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 after receiving 4 doses of rMenB+OMV NZ / MenACWY vaccines, concomitantly administered, versus corresponding response in subjects who received rMenB+OMV NZ administered alone, were presented in terms of vaccine group specific geometric mean titers (GMTs). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

    Time frame: At Day 331 (one month after the fourth vaccination)

  2. hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroups A, C, W-135 and Y

    hSBA titers against N. meningitidis serogroups A, C, W-135 and Y after receiving four doses of either rMenB+OMV NZ / MenACWY concomitantly administered versus corresponding response in subjects who received MenACWY administered alone were presented in terms of vaccine group specific GMTs. This outcome measure applies to only rMenB+ACWY and MenACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

    Time frame: At Day 331 (one month after the fourth vaccination)

Secondary outcomes

  1. hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.

    hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

    Time frame: At Day 1

  2. hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.

    hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

    Time frame: At Day 151 (one month after the third vaccination)

  3. hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.

    hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

    Time frame: At Day 301 (before the fourth vaccination)

  4. hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.

    hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

    Time frame: At Day 331 (one month after the fourth vaccination)

  5. hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.

    hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

    Time frame: At Day 1

  6. hSBA Geometric Mean Titers Against Each of the Serogroups A, C, W-135 and Y

    hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

    Time frame: At Day 151 (one month after the third vaccination)

  7. hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.

    hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

    Time frame: At Day 301 (before the fourth vaccination)

  8. hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.

    hSBA GMTs against each of the N.meningitidis serogroups A, C, W-135, Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

    Time frame: At Day 331 (one month after the fourth vaccination)

  9. Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains

    Percentage of subjects with hSBA titers≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the first vaccination (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

    Time frame: At Day 1

  10. Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains

    Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

    Time frame: At Day 151 (one month after the third vaccination)

  11. Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.

    Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

    Time frame: At Day 301 (before the fourth vaccination)

  12. Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.

    Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

    Time frame: At Day 331 (One month after the fourth vaccination)

  13. Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains

    Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

    Time frame: At Day 1

  14. Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains

    Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at one month after third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

    Time frame: At Day 151 (one month after the third vaccination)

  15. Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains

    Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

    Time frame: At Day 301 (before the fourth vaccination)

  16. Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroup B Indicator Strains

    Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

    Time frame: At Day 331 (one month after the fourth vaccination)

  17. Percentage of Subjects With hSBA Titers ≥1:4 Against Each of the Serogroups A, C, W-135 and Y

    Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the first vaccination (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

    Time frame: At Day 1

  18. Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y

    Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

    Time frame: At Day 151 (one month after the third vaccination)

  19. Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y

    Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

    Time frame: At Day 301 (before the fourth vaccination)

  20. Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y

    Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

    Time frame: At Day 331 (one month after the fourth vaccination)

  21. Within-subject Geometric Mean Ratios (GMRs) Against Each of the Serogroup B Indicator Strains

    Geometric Mean Ratios(GMRs) of GMTs against each of the serogroup B indicator strains- H44/76, 5/99, N98/254 \& M10713 were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination(Day 301).

    Time frame: At Day 331 (one month after fourth vaccination)

  22. Within-subject Geometric Mean Ratios (GMRs) Against Each of Serogroups A, C, W-135 and Y

    Geometric Mean Ratios(GMRs) of GMTs against each of the serogroups A,C,W-135 \& Y were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination (Day 301).

    Time frame: At Day 331 (one month after the fourth vaccination)

  23. Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroup B Indicator Strains

    Percentage of subjects with four-fold increase in hSBA titers against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331) over pre-fourth vaccination (Day 301). This outcome measure applies to only groups rMenB+ACWY and rMenB as the serogroup B indicator strains were assessed only for these two groups. For serogroup B strains, 4-fold increase in titers was defined as post 4th vaccination titer ≥8 (if pre 4th vaccination titer was \<2) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥2).

    Time frame: At Day 331 (one month after the fourth vaccination)

  24. Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroups A, C, W-135 and Y

    Percentages of subjects with four-fold increases in hSBA against each of the N. meningitidis serogroups A,C,W \& Y at one month after the fourth vaccination (Day 331) over pre-fourth vaccination(Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups. For serogroups A, C, W and Y, 4-fold increase in titers was defined as post 4th vaccination titer ≥16 (if pre 4th vaccination titer was \<4) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥4).

    Time frame: At Day 331 (one month after the fourth vaccination)

  25. Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y

    Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 and Y at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

    Time frame: At Day 1

  26. Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y

    Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

    Time frame: At Day 151 (one month before the third vaccination)

  27. Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y

    Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

    Time frame: At Day 301 (before the fourth vaccination)

  28. Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y

    Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

    Time frame: At Day 331 (one month after the fourth vaccination)

  29. Number of Subjects With Solicited Local and Systemic Adverse Events (AEs)

    Number of subjects with solicited local and systemic AEs during the 7 days (including the day of vaccination) after any vaccination

    Time frame: From Day 1 (6 hours) to Day 7 after each vaccination (Days 1, 61, 121 and 301)

  30. Number of Subjects With Unsolicited Adverse Events

    An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.

    Time frame: From Day 1 to Day 7 after each vaccination (Days 1, 61, 121 and 301)

  31. Number of Subjects With SAEs, AEs Leading to Withdrawal and Medically Attended AEs (MAEs)

    A serious adverse event is any untoward medical occurrence that at any dose results in death/ is life threatening/requires prolonged hospitalization/Persistent or significant disability/incapacity/congenital anomaly/or birth defect.

    Time frame: Throughout the whole study period (from Day 1 upto Day 331)

07

Results

Posted Aug 22, 2018

Participant flow

750 healthy infants, aged 3 months were recruited from 3 sites in Argentina and 4 sites in Mexico.

Participant flow — Overall Study
MilestonerMenB+ACWY GrouprMenB GroupMenACWY Group
Started252250248
Completed203202205
Not completed494843
Withdrew: Withdrawal by subject151615
Withdrew: Lost to follow-up252013
Withdrew: Other: administrative reason8512
Withdrew: Other: unspecified142
Withdrew: Adverse event021
Withdrew: Protocol violation010

Outcome measures

PrimaryHuman Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against Each of the Serogroup B Indicator Strains

Human serum bactericidal activity (hSBA) titers against each of the serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 after receiving 4 doses of rMenB+OMV NZ / MenACWY vaccines, concomitantly administered, versus corresponding response in subjects who received rMenB+OMV NZ administered alone, were presented in terms of vaccine group specific geometric mean titers (GMTs). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Geometric mean · Titers
Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against Each of the Serogroup B Indicator Strains
TitersrMenB+ACWY GrouprMenB Group
H44/7692 (67 to 128)104 (77 to 141)
5/991850 (1122 to 3050)1790 (1128 to 2842)
NZ98/25439 (29 to 53)38 (28 to 52)
M1071313 (7.82 to 21)12 (7.72 to 20)
Statistical analysis
  • rMenB+ACWY Group vs rMenB Group · ANOVA · Gmt ratio: 0.89 · 95% CI 0.71 to 1.10The 2-sided 95% CI for each between groups ratio of GMTs was constructed from an analysis of ANOVA with vaccine group \& center as factors in the model
  • rMenB+ACWY Group vs rMenB Group · ANOVA · Gmt ratio: 1.03 · 95% CI 0.74 to 1.45The 2-sided 95% CI for each between groups ratio of GMTs was constructed from an analysis of ANOVA with vaccine group \& center as factors in the model
  • rMenB+ACWY Group vs rMenB Group · ANOVA · Gmt ratio: 1.01 · 95% CI 0.82 to 1.25The 2-sided 95% CI for each between groups ratio of GMTs was constructed from an analysis of ANOVA with vaccine group \& center as factors in the model
  • rMenB+ACWY Group vs rMenB Group · ANOVA · Gmt ratio: 1.03 · 95% CI 0.77 to 1.40The 2-sided 95% CI for each between groups ratio of GMTs was constructed from an analysis of ANOVA with vaccine group \& center as factors in the model
PrimaryhSBA Geometric Mean Titers (GMTs) Against Each of the Serogroups A, C, W-135 and Y

hSBA titers against N. meningitidis serogroups A, C, W-135 and Y after receiving four doses of either rMenB+OMV NZ / MenACWY concomitantly administered versus corresponding response in subjects who received MenACWY administered alone were presented in terms of vaccine group specific GMTs. This outcome measure applies to only rMenB+ACWY and MenACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroups A, C, W-135 and Y
TitersrMenB+ACWY GroupMenACWY Group
Serogroup A409 (300 to 556)165 (122 to 224)
Serogroup C452 (312 to 655)421 (294 to 602)
Serogroup W721 (493 to 1053)536 (370 to 776)
Serogroup Y410 (293 to 575)391 (280 to 546)
Statistical analysis
  • rMenB+ACWY Group vs MenACWY Group · ANOVA · Gmt ratio: 2.48 · 95% CI 1.97 to 3.11The 2-sided 95% CI for each between groups ratio of GMTs was constructed from an analysis of ANOVA with vaccine group \& center as factors in the model
  • rMenB+ACWY Group vs MenACWY Group · ANOVA · Gmt ratio: 1.07 · 95% CI 0.83 to 1.38The 2-sided 95% CI for each between groups ratio of GMTs was constructed from an analysis of ANOVA with vaccine group \& center as factors in the model
  • rMenB+ACWY Group vs MenACWY Group · ANOVA · Gmt ratio: 1.34 · 95% CI 1.04 to 1.74The 2-sided 95% CI for each between groups ratio of GMTs was constructed from an analysis of ANOVA with vaccine group \& center as factors in the model
  • rMenB+ACWY Group vs MenACWY Group · ANOVA · Gmt ratio: 1.05 · 95% CI 0.82 to 1.35The 2-sided 95% CI for each between groups ratio of GMTs was constructed from an analysis of ANOVA with vaccine group \& center as factors in the model
SecondaryhSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.

hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

Time frame:
At Day 1
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
TitersrMenB+ACWY GrouprMenB Group
H44/761.03 (0.99 to 1.08)1.02 (0.98 to 1.07)
5/991.09 (0.99 to 1.21)1.07 (0.97 to 1.17)
NZ98/2541.06 (1.01 to 1.12)1.07 (1.02 to 1.12)
M107131.88 (1.51 to 2.34)1.59 (1.29 to 1.96)
SecondaryhSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.

hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

Time frame:
At Day 151 (one month after the third vaccination)
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
TitersrMenB+ACWY GrouprMenB Group
H44/76116 (100 to 135)129 (113 to 147)
5/99891 (752 to 1055)935 (803 to 1088)
NZ98/25432 (26 to 39)33 (27 to 40)
M107139.09 (6.57 to 13)10 (7.50 to 14)
SecondaryhSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.

hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

Time frame:
At Day 301 (before the fourth vaccination)
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
TitersrMenB+ACWY GrouprMenB Group
H44/767.68 (5.91 to 9.99)8.31 (6.54 to 11)
5/99131 (107 to 161)109 (90 to 132)
NZ98/2543.21 (2.44 to 4.21)2.93 (2.25 to 3.81)
M107132.48 (1.89 to 3.27)2.40 (1.85 to 3.10)
SecondaryhSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.

hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
TitersrMenB+ACWY GrouprMenB Group
H44/76122 (98 to 151)126 (104 to 154)
5/991404 (1016 to 1939)1262 (934 to 1706)
NZ98/25437 (30 to 45)36 (30 to 44)
M1071318 (14 to 24)17 (13 to 22)
SecondaryhSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.

hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

Time frame:
At Day 1
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.
TitersrMenB+ACWY GroupMenACWY Group
Serogroup A2.05 (1.97 to 2.15)2.08 (1.99 to 2.17)
Serogroup C2.16 (1.98 to 2.35)2.09 (1.92 to 2.27)
Serogroup W2.33 (2.13 to 2.55)2.31 (2.11 to 2.52)
Serogroup Y2.06 (1.95 to 2.17)2.16 (2.05 to 2.28)
SecondaryhSBA Geometric Mean Titers Against Each of the Serogroups A, C, W-135 and Y

hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

Time frame:
At Day 151 (one month after the third vaccination)
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers Against Each of the Serogroups A, C, W-135 and Y
TitersrMenB+ACWY GroupMenACWY Group
Serogroup A303 (242 to 379)136 (108 to 169)
Serogroup C388 (320 to 469)416 (345 to 502)
Serogroup W347 (282 to 427)298 (244 to 364)
Serogroup Y226 (182 to 282)283 (228 to 351)
SecondaryhSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.

hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

Time frame:
At Day 301 (before the fourth vaccination)
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.
TitersrMenB+ACWY GroupMenACWY Group
Serogroup A20 (15 to 28)15 (11 to 21)
Serogroup C31 (23 to 41)43 (32 to 58)
Serogroup W48 (37 to 63)47 (36 to 62)
Serogroup Y38 (30 to 49)43 (33 to 55)
SecondaryhSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.

hSBA GMTs against each of the N.meningitidis serogroups A, C, W-135, Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 \& Y were assessed only for these two groups.

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Geometric mean · Titers
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.
TitersrMenB+ACWY GroupMenACWY Group
Serogroup A329 (269 to 403)132 (108 to 161)
Serogroup C331 (268 to 409)311 (252 to 384)
Serogroup W576 (458 to 723)428 (342 to 537)
Serogroup Y377 (304 to 466)363 (294 to 448)
SecondaryPercentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains

Percentage of subjects with hSBA titers≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the first vaccination (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.

Time frame:
At Day 1
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains
Percentage of subjectsrMenB+ACWY GrouprMenB Group
H44/760 (0.0 to 2.3)1 (0.01 to 2.8)
5/991 (0.15 to 4.5)1 (0.13 to 3.7)
NZ98/2541 (0.01 to 2.9)1 (0.01 to 2.7)
M1071316 (11.4 to 22.7)11 (6.9 to 15.9)
SecondaryPercentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains

Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

Time frame:
At Day 151 (one month after the third vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains
Percentage of subjectsrMenB+ACWY GrouprMenB Group
H44/76100 (97.6 to 100.0)100 (98.2 to 100.0)
5/99100 (97.3 to 100.0)100 (98.1 to 100.0)
NZ98/25496 (92.2 to 98.4)97 (93.7 to 98.9)
M1071370 (62.7 to 77.0)68 (61.1 to 74.3)
SecondaryPercentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.

Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

Time frame:
At Day 301 (before the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.
Percentage of subjectsrMenB+ACWY GrouprMenB Group
H44/7674 (65.4 to 81.2)75 (67.9 to 80.7)
5/99100 (97.4 to 100.0)97 (93.9 to 99.1)
NZ98/25442 (34.2 to 49.3)36 (29.7 to 43.3)
M1071333 (25.7 to 41.2)31 (24.5 to 37.7)
SecondaryPercentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.

Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

Time frame:
At Day 331 (One month after the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.
Percentage of subjectsrMenB+ACWY GrouprMenB Group
H44/76100 (97.4 to 100.0)99 (97.1 to 99.99)
5/9999 (95.0 to 99.83)97 (93.0 to 98.8)
NZ98/254100 (98.0 to 100.0)98 (94.9 to 99.4)
M1071387 (80.8 to 91.7)87 (81.6 to 91.5)
SecondaryPercentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains

Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

Time frame:
At Day 1
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains
Percentage of subjectsrMenB+ACWY GrouprMenB Group
H44/760 (0.0 to 2.3)0 (0.0 to 1.8)
5/991 (0.02 to 3.5)1 (0.01 to 2.9)
NZ98/2541 (0.01 to 2.9)1 (0.01 to 2.7)
M1071312 (7.3 to 17.1)8 (4.6 to 12.5)
SecondaryPercentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains

Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at one month after third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

Time frame:
At Day 151 (one month after the third vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains
Percentage of subjectsrMenB+ACWY GrouprMenB Group
H44/76100 (97.6 to 100.0)100 (98.2 to 100.0)
5/99100 (97.3 to 100.0)100 (98.1 to 100.0)
NZ98/25492 (87.4 to 95.7)92 (87.6 to 95.5)
M1071365 (57.2 to 72.1)59 (52.2 to 66.0)
SecondaryPercentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains

Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

Time frame:
At Day 301 (before the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains
Percentage of subjectsrMenB+ACWY GrouprMenB Group
H44/7658 (49.5 to 67.0)56 (48.9 to 63.5)
5/99100 (97.4 to 100.0)97 (93.2 to 98.8)
NZ98/25426 (19.6 to 33.2)26 (20.6 to 33.1)
M1071321 (14.4 to 27.9)23 (17.5 to 29.7)
SecondaryPercentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroup B Indicator Strains

Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroup B Indicator Strains
Percentage of subjectsrMenB+ACWY GrouprMenB Group
H44/76100 (97.4 to 100.0)99 (97.1 to 99.99)
5/9999 (95.0 to 99.83)97 (93.0 to 98.8)
NZ98/25498 (94.4 to 99.4)94 (90.2 to 97.2)
M1071383 (76.5 to 88.6)82 (76.4 to 87.5)
SecondaryPercentage of Subjects With hSBA Titers ≥1:4 Against Each of the Serogroups A, C, W-135 and Y

Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the first vaccination (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

Time frame:
At Day 1
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers ≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjectsrMenB+ACWY GroupMenACWY Group
Serogroup A1 (0.11 to 3.4)1 (0.12 to 3.5)
Serogroup C4 (1.7 to 7.5)3 (1.4 to 6.9)
Serogroup W4 (1.8 to 8.0)4 (1.4 to 7.2)
Serogroup Y2 (0.5 to 4.7)5 (2.3 to 8.6)
SecondaryPercentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y

Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

Time frame:
At Day 151 (one month after the third vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjectsrMenB+ACWY GroupMenACWY Group
Serogroup A99 (97.4 to 99.99)96 (92.0 to 98.0)
Serogroup C100 (98.2 to 100.0)100 (98.2 to 100.0)
Serogroup W100 (97.9 to 100.0)100 (98.1 to 100.0)
Serogroup Y99 (96.0 to 99.71)100 (98.3 to 100.0)
SecondaryPercentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y

Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

Time frame:
At Day 301 (before the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjectsrMenB+ACWY GroupMenACWY Group
Serogroup A68 (60.5 to 73.9)63 (55.4 to 69.2)
Serogroup C88 (82.3 to 92.0)89 (84.1 to 93.4)
Serogroup W93 (88.7 to 96.7)96 (91.3 to 98.0)
Serogroup Y91 (85.8 to 94.3)95 (90.6 to 97.3)
SecondaryPercentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y

Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjectsrMenB+ACWY GroupMenACWY Group
Serogroup A100 (98.1 to 100.0)98 (94.3 to 99.2)
Serogroup C100 (98.1 to 100.0)100 (98.1 to 100.0)
Serogroup W100 (98.0 to 100.0)100 (98.0 to 100.0)
Serogroup Y100 (98.2 to 100.0)99 (97.3 to 99.99)
SecondaryWithin-subject Geometric Mean Ratios (GMRs) Against Each of the Serogroup B Indicator Strains

Geometric Mean Ratios(GMRs) of GMTs against each of the serogroup B indicator strains- H44/76, 5/99, N98/254 \& M10713 were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination(Day 301).

Time frame:
At Day 331 (one month after fourth vaccination)
Reported as:
Geometric mean · Ratio
Within-subject Geometric Mean Ratios (GMRs) Against Each of the Serogroup B Indicator Strains
RatiorMenB+ACWY GrouprMenB Group
H44/7617 (13 to 22)16 (12 to 20)
5/999.60 (6.99 to 13)12 (8.86 to 16)
NZ98/25411 (8.35 to 15)12 (9.39 to 16)
M107135.99 (4.20 to 8.54)6.75 (4.90 to 9.29)
SecondaryWithin-subject Geometric Mean Ratios (GMRs) Against Each of Serogroups A, C, W-135 and Y

Geometric Mean Ratios(GMRs) of GMTs against each of the serogroups A,C,W-135 \& Y were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination (Day 301).

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Geometric mean · Ratio
Within-subject Geometric Mean Ratios (GMRs) Against Each of Serogroups A, C, W-135 and Y
RatiorMenB+ACWY GroupMenACWY Group
Serogroup A16 (13 to 21)8.75 (6.69 to 11)
Serogroup C11 (8.86 to 14)7.79 (6.25 to 9.71)
Serogroup W13 (10 to 16)9.44 (7.52 to 12)
Serogroup Y9.75 (8.00 to 12)8.97 (7.36 to 11)
SecondaryPercentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroup B Indicator Strains

Percentage of subjects with four-fold increase in hSBA titers against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 \& M10713 at one month after the fourth vaccination (Day 331) over pre-fourth vaccination (Day 301). This outcome measure applies to only groups rMenB+ACWY and rMenB as the serogroup B indicator strains were assessed only for these two groups. For serogroup B strains, 4-fold increase in titers was defined as post 4th vaccination titer ≥8 (if pre 4th vaccination titer was \<2) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥2).

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroup B Indicator Strains
Percentage of subjectsrMenB+ACWY GrouprMenB Group
H44/7693 (86.0 to 96.8)92 (87.2 to 95.6)
5/9994 (88.2 to 97.6)95 (90.9 to 97.9)
NZ98/25481 (73.5 to 86.5)79 (73.1 to 84.9)
M1071358 (48.7 to 66.3)60 (52.5 to 67.0)
SecondaryPercentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroups A, C, W-135 and Y

Percentages of subjects with four-fold increases in hSBA against each of the N. meningitidis serogroups A,C,W \& Y at one month after the fourth vaccination (Day 331) over pre-fourth vaccination(Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups. For serogroups A, C, W and Y, 4-fold increase in titers was defined as post 4th vaccination titer ≥16 (if pre 4th vaccination titer was \<4) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥4).

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjectsrMenB+ACWY GroupMenACWY Group
Serogroup A90 (84.4 to 93.5)71 (64.6 to 77.6)
Serogroup C88 (81.9 to 92.0)77 (70.1 to 82.9)
Serogroup W89 (83.0 to 93.5)84 (77.9 to 89.7)
Serogroup Y82 (75.6 to 86.9)81 (74.4 to 85.8)
SecondaryPercentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y

Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 and Y at baseline (Day 1). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

Time frame:
At Day 1
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjectsrMenB+ACWY GroupMenACWY Group
Serogroup A1 (0.01 to 2.6)1 (0.01 to 2.7)
Serogroup C2 (0.8 to 5.6)2 (0.5 to 4.9)
Serogroup W4 (1.5 to 7.3)3 (0.8 to 5.9)
Serogroup Y0 (0.0 to 1.7)2 (0.5 to 4.8)
SecondaryPercentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y

Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

Time frame:
At Day 151 (one month before the third vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjectsrMenB+ACWY GroupMenACWY Group
Serogroup A99 (97.4 to 99.99)96 (92.0 to 98.0)
Serogroup C100 (98.2 to 100.0)100 (98.2 to 100.0)
Serogroup W100 (97.9 to 100.0)99 (97.1 to 99.99)
Serogroup Y98 (95.3 to 99.5)99 (97.4 to 99.99)
SecondaryPercentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y

Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

Time frame:
At Day 301 (before the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjectsrMenB+ACWY GroupMenACWY Group
Serogroup A65 (58.0 to 71.6)58 (50.8 to 64.9)
Serogroup C77 (70.5 to 82.7)85 (79.3 to 89.9)
Serogroup W92 (86.5 to 95.4)91 (85.8 to 94.8)
Serogroup Y86 (80.1 to 90.2)91 (85.8 to 94.3)
SecondaryPercentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y

Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 \& Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

Time frame:
At Day 331 (one month after the fourth vaccination)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Percentage of subjectsrMenB+ACWY GroupMenACWY Group
Serogroup A100 (98.1 to 100.0)96 (92.4 to 98.3)
Serogroup C99 (97.1 to 99.99)100 (98.1 to 100.0)
Serogroup W100 (98.0 to 100.0)100 (98.0 to 100.0)
Serogroup Y98 (95.7 to 99.69)99 (97.3 to 99.99)
SecondaryNumber of Subjects With Solicited Local and Systemic Adverse Events (AEs)

Number of subjects with solicited local and systemic AEs during the 7 days (including the day of vaccination) after any vaccination

Time frame:
From Day 1 (6 hours) to Day 7 after each vaccination (Days 1, 61, 121 and 301)
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local and Systemic Adverse Events (AEs)
ParticipantsrMenB+ACWY GrouprMenB GroupMenACWY Group
Any235226194
Any local220214157
Any Systemic217217178
Erythema (vaccination 1)10110244
Induration (vaccination 1)11110222
Swelling (vaccination 1)828622
Tenderness (vaccination 1)16215973
Change in Eating Habits (vaccination 1)534734
Diarrhea (vaccination 1)464142
Irritability (vaccination 1)11112187
Persistent Crying (vaccination 1)12413285
Rash (vaccination 1)192818
Sleepiness (vaccination 1)697854
Vomiting (vaccination 1)142823
Fever (vaccination 1)495410
Treatment of Pain/Fever (vaccination 1)829825
Erythema (vaccination 2)9710247
Induration (vaccination 2)9911032
Swelling (vaccination 2)788324
Tenderness (vaccination 2)14213866
Change in Eating Habits (vaccination 2)464431
Diarrhea (vaccination 2)373624
Irritability (vaccination 2)999570
Persistent Crying (vaccination 2)10410866
Rash (vaccination 2)162113
Sleepiness (vaccination 2)515545
Vomiting (vaccination 2)102117
Fever (vaccination 2)485415
Treatment of Pain/Fever (vaccination 2)749129
Erythema (vaccination 3)869635
Induration (vaccination 3)9210330
Swelling (vaccination 3)738219
Tenderness (vaccination 3)13912859
Change in Eating Habits (vaccination 3)424533
Diarrhea (vaccination 3)244025
Irritability (vaccination 3)838461
Persistent Crying (vaccination 3)909260
Rash (vaccination 3)101111
Sleepiness (vaccination 3)394639
Vomiting (vaccination 3)72714
Fever (vaccination 3)373825
Treatment of Pain/Fever (vaccination 3)576931
Erythema (vaccination 4)738837
Induration (vaccination 4)849329
Swelling (vaccination 4)757421
Tenderness (vaccination 4)12612964
Change in Eating Habits (vaccination 4)594540
Diarrhea (vaccination 4)292823
Irritability (vaccination 4)817457
Persistent Crying (vaccination 4)848956
Rash (vaccination 4)11136
Sleepiness (vaccination 4)503733
Vomiting (vaccination 4)151411
Fever (vaccination 4)534619
Treatment of Pain/Fever (vaccination 4)716731
SecondaryNumber of Subjects With Unsolicited Adverse Events

An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.

Time frame:
From Day 1 to Day 7 after each vaccination (Days 1, 61, 121 and 301)
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events
ParticipantsrMenB+ACWY GrouprMenB GroupMenACWY Group
Any10311670
Any unsolicited AEs( vaccination 1)636220
Any unsolicited AEs( vaccination 2)606929
Any unsolicited AEs( vaccination 3)576323
Any unsolicited AEs( vaccination 4)445813
SecondaryNumber of Subjects With SAEs, AEs Leading to Withdrawal and Medically Attended AEs (MAEs)

A serious adverse event is any untoward medical occurrence that at any dose results in death/ is life threatening/requires prolonged hospitalization/Persistent or significant disability/incapacity/congenital anomaly/or birth defect.

Time frame:
Throughout the whole study period (from Day 1 upto Day 331)
Reported as:
Count of participants · Participants
Number of Subjects With SAEs, AEs Leading to Withdrawal and Medically Attended AEs (MAEs)
ParticipantsrMenB+ACWY GrouprMenB GroupMenACWY Group
Any SAEs61311
Any Medically Attended AEs177188183
Any AEs leading to premature withdrawal021

Adverse events

Collected over Solicited local and systemic AEs were collected from day 1 (6 hours) upto day 7 after each vaccination. Unsolicited AEs were collected from day 1 to day 7.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rMenB+ACWY Group0/249 (0%)6/249 (2.4%)240/249 (96.4%)
rMenB Group0/249 (0%)13/249 (5.2%)232/249 (93.2%)
MenACWY Group0/246 (0%)11/246 (4.5%)221/246 (89.8%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventrMenB+ACWY GrouprMenB GroupMenACWY Group
BronchiolitisInfections and infestations1/2493/2494/246
Pneumonia bacterialInfections and infestations1/2493/2491/246
GastroenteritisInfections and infestations1/2492/2490/246
PneumoniaInfections and infestations0/2492/2491/246
Milk allergyImmune system disorders0/2490/2491/246
PertussisInfections and infestations0/2490/2491/246
Urinary tract infectionInfections and infestations1/2490/2491/246
Skull fractureInjury, poisoning and procedural complications0/2490/2491/246
Febrile convulsionNervous system disorders0/2490/2491/246
BronchospasmRespiratory, thoracic and mediastinal disorders0/2490/2491/246
Most frequent other events
Showing 10 of 25
Most frequent other events
EventrMenB+ACWY GrouprMenB GroupMenACWY Group
Injection site painGeneral disorders212/249207/249131/246
CryingGeneral disorders176/249184/249129/246
IrritabilityPsychiatric disorders155/249170/249125/246
Injection site erythemaGeneral disorders147/249162/249104/246
Injection site indurationGeneral disorders144/249152/24957/246
Injection site swellingGeneral disorders130/249138/24956/246
PyrexiaGeneral disorders125/249121/24960/246
SomnolenceNervous system disorders106/249115/24987/246
Eating disorderPsychiatric disorders110/249100/24985/246
DiarrhoeaGastrointestinal disorders108/24998/24989/246

Baseline characteristics

Age, Continuous
Age, Continuous(Days)rMenB+ACWY GrouprMenB GroupMenACWY GroupTotal
Mean104.0 ± 10.72101.4 ± 10.57102.7 ± 10.9102.7 ± 10.77
Sex: Female, Male
Sex: Female, Male(Participants)rMenB+ACWY GrouprMenB GroupMenACWY GroupTotal
Female120118139377
Male132132109373
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)rMenB+ACWY GrouprMenB GroupMenACWY GroupTotal
White17201754
Other235230231696
08

Study locations

7 sites
  • GSK Investigational Site
    Buenos Aires, C1425DEM, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425EFD, Argentina
  • GSK Investigational Site
    Cordoba, X5000JRD, Argentina
  • GSK Investigational Site
    Mexico City, 04530, Mexico
  • GSK Investigational Site
    Mexico City, 06400, Mexico
  • GSK Investigational Site
    Mexico City, 06760, Mexico
  • GSK Investigational Site
    Morelia, 58070, Mexico
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Oct 2016, 28 months.

Results were first posted in Aug 2018, 1 year 10 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 28 months is above that.

Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2014
First posted
Apr 8, 2014
StartActual
Jun 5, 2014
Primary completionActual
Oct 14, 2016
CompletionActual
Oct 14, 2016
Results first posted
Aug 22, 2018
Last update
Aug 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02106390
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 8, 2014
Start date
Jun 5, 2014
Primary completion
Oct 14, 2016
Completion
Oct 14, 2016
Results posted
Aug 22, 2018
Last update
Aug 22, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion